Fate, MSKCC expand off-the-shelf cell therapy deal

Memorial Sloan Kettering Cancer Center and Fate Therapeutics Inc. (NASDAQ:FATE) expanded a 2016 deal on Wednesday, granting Fate exclusive rights to additional IP that covers CAR

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE